UBS Group’s Addex Therapeutics ADXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $268 | Buy |
+47
| New | +$309 | ﹤0.01% | 9950 |
|
|
2026
Q1 | – | Sell |
-156
| Closed | -$1.2K | – | 10414 |
|
|
2025
Q4 | $1.2K | Buy |
156
+155
| +15,500% | +$1.33K | ﹤0.01% | 9661 |
|
|
2025
Q3 | $9 | Buy |
+1
| New | +$9 | ﹤0.01% | 10196 |
|
|
2023
Q4 | – | Sell |
-4
| Closed | -$28 | – | 9235 |
|
|
2023
Q3 | $28 | Buy |
+4
| New | +$40 | ﹤0.01% | 9086 |
|
|
2023
Q1 | – | Sell |
-726
| Closed | -$9.15K | – | 9537 |
|
|
2022
Q4 | $9.15K | Buy |
726
+374
| +106% | +$5.52K | ﹤0.01% | 8685 |
|
|
2022
Q3 | $6K | Sell |
352
-46
| -12% | -$1.03K | ﹤0.01% | 8991 |
|
|
2022
Q2 | $9K | Buy |
398
+258
| +184% | +$19.4K | ﹤0.01% | 8109 |
|
|
2022
Q1 | $14K | Sell |
140
-725
| -84% | -$79.2K | ﹤0.01% | 7917 |
|
|
2021
Q4 | $109K | Buy |
865
+215
| +33% | +$32.4K | ﹤0.01% | 6237 |
|
|
2021
Q3 | $117K | Buy |
650
+14
| +2% | +$2.7K | ﹤0.01% | 5718 |
|
|
2021
Q2 | $122K | Buy |
636
+510
| +405% | +$104K | ﹤0.01% | 5724 |
|
|
2021
Q1 | $26K | Buy |
126
+121
| +2,420% | +$27.1K | ﹤0.01% | 7121 |
|
|
2020
Q4 | $1K | Sell |
5
-52
| -91% | -$12.9K | ﹤0.01% | 8190 |
|
|
2020
Q3 | $14K | Buy |
+57
| New | +$13.8K | ﹤0.01% | 6566 |
|
Other funds holding ADXN
UBS Group's ADXN Position: Q2 2026 in Review
UBS Group opened a new position in Addex Therapeutics (ADXN) in Q2 2026: 47 shares worth $268. The stake represents ﹤0.01% of the portfolio and ranks #9950 among its holdings. This is a return to the name: UBS Group previously reported a position in ADXN as recently as Q4 2025.
UBS Group first reported a position in ADXN in Q3 2020 and has held it in 14 quarters since. The position peaked at $122K in Q2 2021. 2 funds tracked by Wall St. Rank hold ADXN as of Q2 2026.
- UBS Group held 47 shares of Addex Therapeutics worth $268 as of Q2 2026.
- Addex Therapeutics was a new UBS Group position in Q2 2026.
- Addex Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9950 holding.
- UBS Group first reported a position in Addex Therapeutics in Q3 2020 and has held it in 14 quarters since.
- UBS Group's Addex Therapeutics position peaked at $122K in Q2 2021.
- 2 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.